

## AtCor Launches Key Opinion Leader Webinar Series

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor® system for advanced hypertension management, announced today the expansion of its education program through a webinar series featuring Key Opinion Leaders (KOLs) in hypertension and preventative arteriovascular health management. The webinars are designed to educate physicians on best practices for integrating SphygmoCor into clinical practice in a convenient, interactive format. By understanding the additional information provided by SphygmoCor, physicians are then better able to manage patient risk factors of elevated blood pressure and arterial stiffness and subsequently reduce end organ damage associated with many everyday medical conditions including heart attack, stroke and dementia.

The first webinar entitled “**Central Pressure Waveform Analysis in Clinical Practice**” will be presented by Lee S. Marcus, M.D., M.S., F.A.C.C on Thursday 29 September at 12:00pm US eastern daylight time (EDST). More than 100 doctors have already pre-registered. The webinar will be available on AtCor’s website after the event.

Dr. Marcus, the founder of Preventive Cardiology of New York, has been using SphygmoCor in his practice for over one year. He is an enthusiastic supporter of its benefits, stating: “SphygmoCor is an integral component of my cardiovascular risk assessment. The information derived contributes directly to the management of my patients with hypertension, as well as pre-hypertension, allowing me to quickly assess the effects of treatment and lifestyle changes.”

New users also speak about the benefits of using SphygmoCor including Ricardo Cordido, M.D and founder of Heart Care Associates of Connecticut, who leased 3 SphygmoCor systems in June 2016. Commenting, Dr. Cordido said “I recently incorporated SphygmoCor into my hypertension practice and I have been very pleased with the results. I have found the SphygmoCor system to be clinically valuable for total hypertension management. It provides important additional information that has already helped me make better treatment decisions for my patients. As the first in our region to offer this new technology, I will soon begin educating our referring physicians on SphygmoCor for advanced hypertension management.”

### About AtCor Medical

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company’s SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements. SphygmoCor is essential for hypertension management.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com).

*For further information, please contact (AtCor):*

Duncan Ross – AtCor Medical CEO  
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO  
+61 (2) 8815 8811

*Media enquiries to:*

Ashley Rambukwella – Financial &  
Corporate Relations  
Ph: +61 (2) 8264 1004/ m. 0407 231 282  
or [a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)